Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

1
Ovarian Cancer Therapeutics in Asia-Pacific
Markets to 2020 - Off-patent Chemo-regimens to
Retain Dominance Despite New Launches
Single User License - 4995 Site User
License - 9990 Corporate User License -
14985 Publication Date - Jan 2015 Pages -
126 To know more details, email to
debora_at_reportstack.com
2
Summary

• This report provides estimates of the market size
  for 2013, along with forecasts until 2020 for the
  Asia-Pacific markets of India, China, Australia
  and Japan. It also covers disease epidemiology,
  treatment algorithms, treatment patterns,
  in-depth analysis of clinical trials including
  failure rates and pipeline analysis, and analysis
  of deals relevant to Ovarian Cancer (OC).
• Platinum-based chemotherapy, predominantly the
  chemotherapy regimen paclitaxel and carboplatin,
  is the standard of care for the treatment of
  platinum-sensitive OC (both first-line and
  recurrent). The initial treatment is quite
  effective, with the majority of patients entering
  remission. However, almost all relapse, and after
  successive periods of remission and relapse
  either die or progress to platinum-resistant
  disease, for which the prognosis is poor.

3
Scope

• A brief introduction to OC, including the
  diseases pathogenesis, risk factors and
  diagnosis
• In-depth analysis of the drug combinations used
  in the treatment of OC, including analyses of
  their safety, efficacy, and place in the disease
  treatment algorithm, as well as a heat map
  comparing the drug combinations in terms of
  safety and efficacy
• A comprehensive review of the pipeline for OC
  therapies, including individual analysis of a
  number of late-stage pipeline drugs that have the
  potential to enter the market in the forecast
  period the pipeline is analyzed on the basis of
  phase distribution, molecule type and molecular
  target, and route of administration
• Discussion of the drivers and barriers for market
  growth

4
Key Benefits

• Understand the efficacy and safety of the current
  monotherapies and drug combinations used in the
  treatment of OC, with in-depth analysis of the
  disease treatment algorithm
• Understand the key signaling pathways and
  molecular targets currently under investigation
  in OC drug development
• Understand the vast scope of the pipeline,
  including which molecule types and mechanisms of
  action are prominent
• Observe the trends in clinical trial duration and
  size among clinical phases and molecule types,
  and use the clinical trial failure rate analysis
  to assess the risk profiles of current and/or
  future developmental programs for OC therapeutics
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  in the OC therapeutics market

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com